Should You Buy AMETEK Inc (AME) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
BUY for a beginner, long-term investor with $50k–$100k who wants to act now. AME is in a clear uptrend (bullish moving averages and positive MACD), fundamentals are still compounding (double-digit revenue growth and expanding margins in 2025/Q3), and options positioning is bullish (put/call ratios below 1). The main pushback is valuation concerns (recent Oppenheimer downgrade), but the tape and business momentum still support buying at/near ~$220 ahead of the 2026-02-03 earnings catalyst.
Technical Analysis
Trend is bullish. SMA_5 > SMA_20 > SMA_200 confirms strong upward structure. MACD histogram is positive (0.475) but contracting, suggesting upside momentum is still present but cooling slightly. RSI_6 at ~68.6 is near the upper end of neutral (not extreme), consistent with a strong trend that isn’t yet clearly overbought. Key levels: pivot 216.8 is the first “line in the sand”; resistance R1 222.7 then R2 226.3—price around 220 is close to resistance, but the broader trend remains constructive. Pattern-based projection provided is also favorable (higher probability of gains over week/month).
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Analyst Ratings and Price Target Trends
Recent trend is mostly constructive with multiple buys and rising targets, but with one valuation-driven downgrade. Key changes: Deutsche Bank initiated Buy with a $271 PT (bullish on recovery + M&A). KeyBanc raised PT to $235 (Overweight). Mizuho raised PT to $230 (Outperform). Melius upgraded to Buy with $235 PT. TD Cowen upgraded to Buy with $230 PT. Barclays stayed Equal Weight and nudged PT to $210 (more neutral). Oppenheimer downgraded to Perform citing valuation (bearish on upside from here).
Wall Street pro view: high-quality industrial compounder with backlog strength, improving demand pockets (including AI-related), and M&A optionality. Con view: a lot of the growth is already priced in, limiting multiple expansion unless earnings/guidance re-accelerate.
Influential buying/selling: Hedge funds and insiders show no significant recent trend; no recent congress trading data available.
Wall Street analysts forecast AME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AME is 231 USD with a low forecast of 210 USD and a high forecast of 246 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast AME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AME is 231 USD with a low forecast of 210 USD and a high forecast of 246 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 226.620
Current: 226.620
